Home/ Stocks/ CUE

Cue Biopharma, Inc.

CUE XNAS

$35.00 +1.23 (+3.44%) ▲ 15-min delayed

Open

$35.35

High

$36.98

Low

$34.01

Volume

244.6K

Market Cap

$113.94M

About Cue Biopharma, Inc.

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 29 Website →

Key Financials

Period	Revenue	Net Income	EPS
TTM 2025	$27.47M	$-26,602,000	$-0.28
FY 2025	$27.47M	$-26,602,000	$-0.28
Q3 2025	$2.15M	$-7,448,000	$-0.07
Q2 2025	$2.95M	$-8,482,000	$-0.09

TickerDaily Coverage

Stock Market Today, May 1, 2026: Mega Movers Dominate Week as CUE, BIYA Triple

Market News David Brooks · May 1, 2026

Friday, May 1, 2026 closes a wild week of outsized gains driven by a rotation into speculative...

Why Is Cue Biopharma (CUE) Stock Up 127.1% Today?

Market News Alex Chen · May 1, 2026

Cue Biopharma (CUE) stock exploded 127.1% on Friday, May 1, 2026, after the clinical-stage biotech...

View All Coverage →

Get CUE Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Cue Biopharma, Inc..

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.